Pub. Date : 2003 May 15
PMID : 12560222
25 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | Inactivation of the human P2Y12 receptor by thiol reagents requires interaction with both extracellular cysteine residues, Cys17 and Cys270. | Sulfhydryl Compounds | purinergic receptor P2Y12 | Homo sapiens |
| 2 | Inactivation of the human P2Y12 receptor by thiol reagents requires interaction with both extracellular cysteine residues, Cys17 and Cys270. | Cysteine | purinergic receptor P2Y12 | Homo sapiens |
| 3 | The thiol agent p-chloromercuribenzene sulfonic acid (pCMBS) and the active metabolites from antiplatelet drugs, clopidogrel and CS-747, inactivate the P2Y(12) receptor and are predicted to interact with the extracellular cysteine residues on the P2Y(12) receptor. | Sulfhydryl Compounds | purinergic receptor P2Y12 | Homo sapiens |
| 4 | The thiol agent p-chloromercuribenzene sulfonic acid (pCMBS) and the active metabolites from antiplatelet drugs, clopidogrel and CS-747, inactivate the P2Y(12) receptor and are predicted to interact with the extracellular cysteine residues on the P2Y(12) receptor. | Sulfhydryl Compounds | purinergic receptor P2Y12 | Homo sapiens |
| 5 | The thiol agent p-chloromercuribenzene sulfonic acid (pCMBS) and the active metabolites from antiplatelet drugs, clopidogrel and CS-747, inactivate the P2Y(12) receptor and are predicted to interact with the extracellular cysteine residues on the P2Y(12) receptor. | Phosphorus | purinergic receptor P2Y12 | Homo sapiens |
| 6 | The thiol agent p-chloromercuribenzene sulfonic acid (pCMBS) and the active metabolites from antiplatelet drugs, clopidogrel and CS-747, inactivate the P2Y(12) receptor and are predicted to interact with the extracellular cysteine residues on the P2Y(12) receptor. | Phosphorus | purinergic receptor P2Y12 | Homo sapiens |
| 7 | The thiol agent p-chloromercuribenzene sulfonic acid (pCMBS) and the active metabolites from antiplatelet drugs, clopidogrel and CS-747, inactivate the P2Y(12) receptor and are predicted to interact with the extracellular cysteine residues on the P2Y(12) receptor. | chloromercuribenzene sulfonic acid | purinergic receptor P2Y12 | Homo sapiens |
| 8 | The thiol agent p-chloromercuribenzene sulfonic acid (pCMBS) and the active metabolites from antiplatelet drugs, clopidogrel and CS-747, inactivate the P2Y(12) receptor and are predicted to interact with the extracellular cysteine residues on the P2Y(12) receptor. | chloromercuribenzene sulfonic acid | purinergic receptor P2Y12 | Homo sapiens |
| 9 | The thiol agent p-chloromercuribenzene sulfonic acid (pCMBS) and the active metabolites from antiplatelet drugs, clopidogrel and CS-747, inactivate the P2Y(12) receptor and are predicted to interact with the extracellular cysteine residues on the P2Y(12) receptor. | 4-Chloromercuribenzenesulfonate | purinergic receptor P2Y12 | Homo sapiens |
| 10 | The thiol agent p-chloromercuribenzene sulfonic acid (pCMBS) and the active metabolites from antiplatelet drugs, clopidogrel and CS-747, inactivate the P2Y(12) receptor and are predicted to interact with the extracellular cysteine residues on the P2Y(12) receptor. | 4-Chloromercuribenzenesulfonate | purinergic receptor P2Y12 | Homo sapiens |
| 11 | The thiol agent p-chloromercuribenzene sulfonic acid (pCMBS) and the active metabolites from antiplatelet drugs, clopidogrel and CS-747, inactivate the P2Y(12) receptor and are predicted to interact with the extracellular cysteine residues on the P2Y(12) receptor. | Clopidogrel | purinergic receptor P2Y12 | Homo sapiens |
| 12 | The thiol agent p-chloromercuribenzene sulfonic acid (pCMBS) and the active metabolites from antiplatelet drugs, clopidogrel and CS-747, inactivate the P2Y(12) receptor and are predicted to interact with the extracellular cysteine residues on the P2Y(12) receptor. | Clopidogrel | purinergic receptor P2Y12 | Homo sapiens |
| 13 | The thiol agent p-chloromercuribenzene sulfonic acid (pCMBS) and the active metabolites from antiplatelet drugs, clopidogrel and CS-747, inactivate the P2Y(12) receptor and are predicted to interact with the extracellular cysteine residues on the P2Y(12) receptor. | Cesium | purinergic receptor P2Y12 | Homo sapiens |
| 14 | The thiol agent p-chloromercuribenzene sulfonic acid (pCMBS) and the active metabolites from antiplatelet drugs, clopidogrel and CS-747, inactivate the P2Y(12) receptor and are predicted to interact with the extracellular cysteine residues on the P2Y(12) receptor. | Cesium | purinergic receptor P2Y12 | Homo sapiens |
| 15 | The thiol agent p-chloromercuribenzene sulfonic acid (pCMBS) and the active metabolites from antiplatelet drugs, clopidogrel and CS-747, inactivate the P2Y(12) receptor and are predicted to interact with the extracellular cysteine residues on the P2Y(12) receptor. | Cysteine | purinergic receptor P2Y12 | Homo sapiens |
| 16 | In this study we identified the reactive cysteine residues on the human P2Y(12) receptor by site-directed mutagenesis using pCMBS as the thiol reagent. | Cysteine | purinergic receptor P2Y12 | Homo sapiens |
| 17 | In this study we identified the reactive cysteine residues on the human P2Y(12) receptor by site-directed mutagenesis using pCMBS as the thiol reagent. | 4-Chloromercuribenzenesulfonate | purinergic receptor P2Y12 | Homo sapiens |
| 18 | In this study we identified the reactive cysteine residues on the human P2Y(12) receptor by site-directed mutagenesis using pCMBS as the thiol reagent. | Sulfhydryl Compounds | purinergic receptor P2Y12 | Homo sapiens |
| 19 | Cys97Ser and Cys175Ser mutants of the P2Y(12) receptor did not express when transfected into Chinese hamster ovary (CHO-K1) cells, indicating the essential nature of a disulfide bridge between these residues. | Disulfides | purinergic receptor P2Y12 | Homo sapiens |
| 20 | Similarly, the median inhibitory concentration (IC(50)) values for BzATP (2",3"-O-(4- benzoylbenzoyl) adenosine 5"-triphosphate), an antagonist of the P2Y(12) receptor, also did not differ dramatically among these mutants and the wild-type P2Y(12) receptor. | 3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate | purinergic receptor P2Y12 | Homo sapiens |
| 21 | These results indicate that, unlike the P2Y(1) receptor, which has 2 essential disulfide bridges linking its extracellular domains, the P2Y(12) receptor has 2 free cysteines in its extracellular domains (Cys17 and Cys270), both of which are targets of thiol reagents. | Cysteine | purinergic receptor P2Y12 | Homo sapiens |
| 22 | These results indicate that, unlike the P2Y(1) receptor, which has 2 essential disulfide bridges linking its extracellular domains, the P2Y(12) receptor has 2 free cysteines in its extracellular domains (Cys17 and Cys270), both of which are targets of thiol reagents. | Sulfhydryl Compounds | purinergic receptor P2Y12 | Homo sapiens |
| 23 | We speculate that the active metabolites of clopidogrel and CS-747 form disulfide bridges with both Cys17 and Cys270 in the P2Y(12) receptor, and thereby inactivate the receptor. | Clopidogrel | purinergic receptor P2Y12 | Homo sapiens |
| 24 | We speculate that the active metabolites of clopidogrel and CS-747 form disulfide bridges with both Cys17 and Cys270 in the P2Y(12) receptor, and thereby inactivate the receptor. | Cesium | purinergic receptor P2Y12 | Homo sapiens |
| 25 | We speculate that the active metabolites of clopidogrel and CS-747 form disulfide bridges with both Cys17 and Cys270 in the P2Y(12) receptor, and thereby inactivate the receptor. | Disulfides | purinergic receptor P2Y12 | Homo sapiens |